IFNG and tuberculosis: Furthermore, two phase I/II clinical trials (NCT00001407 and NCT05065905) were conducted between 1999 and 2006 to investigate the effects of different doses of IFN‐γ in treating MDR‐TB and the efficacy and safety of IFN‐γ in treating HIV and PTB patients.